Biotech Sector on the Upswing -- Dendreon and ADVENTRX Pharmaceuticals Looking Strong
January 31 2012 - 8:20AM
Marketwired
Biotechnology stocks have been on a tear this month, gaining an
impressive 11 percent. Reuters recently released an article arguing
health-care costs are outpacing consumer inflation, leading
government and industry to seek ways to cut costs. Reuters' 2012
biotech outlook says this could mean an even greater reliance upon
drugs. Five Star Equities examines the outlook for companies in the
Biotechnology industry and provides equity research on Dendreon
Corporation (NASDAQ: DNDN) and ADVENTRX Pharmaceuticals, Inc. (NYSE
Amex: ANX). Access to the full company reports can be found at:
www.fivestarequities.com/DNDN www.fivestarequities.com/ANX
Gunderson Capital Management argues that part of biotech's rally
is being driven by expectations that President Barack Obama's
health care reform plan may be repealed. Earlier this month House
Republicans pushed through a resolution in support of a
Constitutional amendment that would repeal Obamacare. House
Resolution 1003 asks Congress to call a constitutional convention
to propose an amendment to repeal the Affordable Care Act, which is
also set to be challenged before the Supreme Court this year.
Five Star Equities releases regular market updates on the
biotechnology industry so investors can stay ahead of the crowd and
make the best investment decisions to maximize their returns. Take
a few minutes to register with us free at www.fivestarequities.com
and get exclusive access to our numerous stock reports and industry
newsletters.
ADVENTRX's current lead product candidates are ANX-188, a novel,
purified, rheologic and antithrombotic compound initially being
developed as a first-in-class treatment for pediatric patients with
sickle cell disease in acute crisis, and ANX-514, a novel,
detergent-free formulation of the chemotherapy drug docetaxel. In
December ADVENTRX met with the U.S. Food and Drug Administration
(FDA) to review development plans for ANX-188.
Five Star Equities provides Market Research focused on equities
that offer growth opportunities, value, and strong potential
return. We strive to provide the most up-to-date market activities.
We constantly create research reports and newsletters for our
members. Five Star Equities has not been compensated by any of the
above-mentioned companies. We act as an independent research portal
and are aware that all investment entails inherent risks. Please
view the full disclaimer at:
www.fivestarequities.com/disclaimer
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: Five Star Equities Email Contact
Adventrx (AMEX:ANX)
Historical Stock Chart
From May 2024 to Jun 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2023 to Jun 2024